No animal sampled at the Huanan market, in its supply chain, or in China's subsequent wildlife testing has been shown to carry SARS-CoV-2 or a sufficiently close progenitor.

The 457 negatives are real (COV-E006) but narrow: candidate intermediate hosts were never sampled and stock was largely cleared before collection (COV-E007), and WHO doubts the completeness of China's wider animal testing (COV-E008). Credible, but close to non-diagnostic as a negative against zoonosis.

The negatives are real (COV-E006) but narrow: candidate hosts were never sampled and stock was cleared first (COV-E007). COV-E008 now adds WHO's explicit doubt about the completeness of China's reported animal testing, which further drains this observation of diagnosticity without altering its local truth.

The 457 negatives are real but narrow: candidate intermediate hosts were never sampled and stock was largely cleared and disinfected first (COV-E006, COV-E007), and WHO doubts the completeness of China's wider animal testing (COV-E008). Credible, low diagnosticity against zoonosis.

It is universally acknowledged by the Chinese CDC and WHO that no animal sampled in the market, the supply chain, or subsequent testing has tested positive for the virus or a direct progenitor. This constitutes the most glaring empirical deficit for the zoonotic hypothesis. The strongest opposing consideration is that this absence is largely uninformative because the animals actually tested were strays and frozen stock, whereas the highly susceptible candidate species were largely removed before sampling occurred.

Comprehensive testing of 457 animal samples by the Chinese CDC, along with extensive subsequent unverified testing, yielded no SARS-CoV-2-positive results. The absence of an identified animal host in the tested pool is firmly established. However, this absence is weak evidence against zoonosis because the relevant candidate intermediate species sold at the market were entirely missing from the sampled population, which consisted largely of strays and frozen goods.

Extensive testing of 457 animals by the Chinese CDC yielded zero positive results for SARS-CoV-2, a negative finding echoed by WHO assessments of Chinese testing efforts. This represents a massive empirical deficit for the zoonotic hypothesis. The strongest opposing consideration is that the candidate intermediate host species (like civets and raccoon dogs) were never actually sampled before the market was cleared, making the negative results largely uninformative.

COV-E004 and COV-E006 document 457 negative animal PCRs from the market and China’s report of large-scale negative testing, and COV-E008 notes WHO’s skepticism about the completeness of those results—together, they support the factual statement that no infected animal or close progenitor has been shown. The key caveat is that the most relevant live-wildlife species were never sampled, many animals were removed pre-sampling, and post-pandemic testing is unaudited, so this absence is weak as negative evidence about zoonosis.

Liu et al. report all 457 animal samples from 18 species at the market tested negative for SARS‑CoV‑2 (COV-E006), and WHO records China’s broader claim of extensive negative wildlife testing without any counterexample (COV-E007, COV-E008, COV-E009). The key objection is that these samples were largely unsold stock, strays, and freezer contents rather than the live candidate hosts, and that susceptible species were not systematically tested, making this primarily an absence created by incomplete sampling.

The Chinese CDC reports 457 animal samples (unsold stock, freezer contents, and strays) all negative, and WHO records China’s claim of extensive further negative animal testing, while also doubting its completeness. The key counterpoint is that the most relevant live mammals—raccoon dogs, civets, etc.—were never sampled at the market, and WHO notes it is implausible that no human‑to‑animal infections have ever occurred, so these negatives provide weak constraint.

Liu 2024 reports all 457 animal samples negative, drawn from unsold goods, refrigerators and freezers, and strays across 18 species; the 2021 joint study recorded China's broader account of extensive negative wildlife testing. As an observation about what has been shown, the claim is accurate. The strongest opposing consideration is that this absence is largely a fact about sampling design: the later reanalysis states that no raccoon dogs or civets on sale were ever sampled or tested, no animal or handler serology was taken, and SAGO both limits any definitive conclusion to the narrow species range and expresses scepticism that China has truly seen no reverse-zoonotic infections since the pandemic began.

Liu et al. report that all 457 animal samples — unsold stock, freezer contents, and strays from 18 species — tested negative, and the 2021 joint study plus SAGO record China's account of much broader subsequent testing with no positives. The claim is that no sampled animal has been shown to carry the virus or a close progenitor, which matches the published record. SAGO adds that this China-wide negative account has not been independently verified and that the limited range of species tested limits definitive conclusions. Strongest opposing consideration: the candidate intermediate hosts on sale were never sampled, the market was cleared before testing, the upstream traceback was never completed, and an absence produced by not testing the relevant animals is largely uninformative either way.

All 457 animal samples in the Chinese CDC survey tested negative, and the joint WHO-China study recorded China's account of extensive subsequent wildlife testing with no positives; no sampled animal has been shown to carry the virus or a close progenitor. That absence is much weaker than it looks, because the sampled animals were largely unsold stock, freezer contents, and strays, and a later reanalysis states that raccoon dogs and civets on sale were never sampled or tested. The strongest opposing consideration is that this is substantially a fact about what investigators were able to look for after the market was cleared, and WHO additionally finds the reported absence of any reverse zoonoses in China since the pandemic began implausible, which is scepticism about the completeness of the same negative results.

As a statement about the record, the absence is documented from both directions: all 457 animal samples in the market survey tested negative, and the joint WHO study records China's account of tens of thousands of animals tested without positives. The verdict attaches to the absence's existence, not its weight. The strongest opposing consideration is that the absence is substantially manufactured by scope: the sampled animals were unsold stock, strays, and freezer contents; the candidate host species were never sampled; no serology was taken; and WHO itself expressed scepticism about the completeness of China's reported negative results. A well-supported absence of largely uninformative character — true, and weaker than it looks.

All 457 animal samples tested negative, verbatim in the custodian's peer-reviewed report, and the larger national testing figure exists only as China's unaudited account — which the claim's careful wording ("has been shown to carry") does not require. The strongest opposing consideration is that this absence was substantially manufactured: the sampled animals were unsold stock, freezer contents, and strays, the candidate intermediate-host species were never tested, no serology was taken, and WHO itself finds the reported completeness of post-pandemic animal results implausible. That hollows out the absence's diagnosticity but not its accuracy as a statement about the record, which is what the claim asserts; this case correctly treats it as the mirror of the laboratory side's unproduced inventories.

As a negative-existence claim about what has been shown, it is directly supported: all 457 animal samples negative in the Chinese CDC survey, and the joint study records China's unaudited account of mass testing with no positives. The strongest opposing consideration is the scope problem the record itself documents — the sampled animals were unsold stock, strays, and freezer contents; the candidate host species were never sampled; and WHO states the limited species range precludes definitive conclusions while expressing scepticism that China has seen zero reverse zoonoses. So the claim is true and simultaneously much weaker evidence than it appears: an absence produced by not testing the relevant animals. Well supported as stated, near-uninformative as discrimination.

As a statement about the public record it is plainly true: all 457 CCDC animal samples were negative, and no positive animal has ever been produced from the supply chain or from China's subsequent testing. The strongest opposing consideration is not that the claim is false but that it is nearly uninformative — the sampled animals were unsold stock, freezer contents, and strays rather than the candidate hosts, which the reanalysis states were never sampled, and WHO itself doubts the completeness of China's reported post-pandemic animal testing. An absence generated by not testing the relevant species carries little diagnostic weight in either direction.

As a statement about the public record the claim is secure: all 457 CCDC animal samples were negative, and no positive animal has ever been reported from the market, its supply chain, or subsequent Chinese testing. The strongest opposing consideration cuts at interpretation rather than truth — the sampled animals were unsold stock, freezer contents and strays rather than the implicated live wild mammals, and the aggregate national testing figures are the custodian's unaudited account, so an infected animal could have existed and gone untested or a positive gone unreported. WHO's own scepticism that China recorded no reverse zoonoses at all reinforces that the negative record is incomplete. An absence generated by not looking is a weak negative.

As a statement about the public record it is straightforwardly true: all 457 animal samples in the CDC survey were negative, and no positive animal has ever been produced from the market, its supply chain, or subsequent testing. The strongest opposing consideration is not to the claim's truth but to its weight — the sampled animals were unsold stock, freezer contents and strays, the candidate intermediate hosts were never sampled or serologically tested, and WHO itself calls the reported blanket negativity across China implausible. An absence generated by not testing the relevant species is close to uninformative, and I read this as the mirror of COV-C013 rather than as a one-sided deficit.

The negative results are real and narrow: the candidate intermediate-host species were never sampled or tested, which the reanalysis of that dataset states directly.

The negatives are real (COV-E006) and narrow: candidate intermediate hosts were never sampled and the stock was largely cleared first, as SAGO states (COV-E007). Gemini and Grok both note the absence is partly manufactured by sampling design; that is why it does not function as a diagnostic negative against zoonosis.